Advocacy
Learn more about the Association's advocacy efforts to ensure patient
access to therapies.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Apr 12, 2022
Letter to the New York State Department of Health Commissioner: New York’s Clinical Laboratory Regulations
The Plasma Protein Therapeutics Association (PPTA) is writing to request that you please consider expeditiously granting a reasonable and necessary regulatory reform for the SourcePlasma sector pertaining to two of New York’s clinical laboratory regulations.
All
Advocacy
https://assets-global.website-files.com/638f893112c6eac0e46ac576/6453f64c2490bcf9502656fc_Letter_to_NYDOH_Commissioner.pdf
Apr 12, 2022
Letter to the New York State Department of Health Commissioner: New York’s Clinical Laboratory Regulations
The Plasma Protein Therapeutics Association (PPTA) is writing to request that you please consider expeditiously granting a reasonable and necessary regulatory reform for the SourcePlasma sector pertaining to two of New York’s clinical laboratory regulations.
All
Advocacy
https://assets-global.website-files.com/638f893112c6eac0e46ac576/6453f64c2490bcf9502656fc_Letter_to_NYDOH_Commissioner.pdf
Oct 1, 2021
Together toward a broader European plasma donation ecosystem
Strengthening the EU Blood Directive: To meet the needs of patients using plasma-derived medicinal products and plasma donors
All
Advocacy
https://assets-global.website-files.com/638f893112c6eac0e46ac576/6453f652d7ca1569557512dc_PPTA%20Position%20Paper%20on%20the%20EU%20BTC%20revision_September2021.pdf
Oct 1, 2021
Together toward a broader European plasma donation ecosystem
Strengthening the EU Blood Directive: To meet the needs of patients using plasma-derived medicinal products and plasma donors
All
Advocacy
https://assets-global.website-files.com/638f893112c6eac0e46ac576/6453f652d7ca1569557512dc_PPTA%20Position%20Paper%20on%20the%20EU%20BTC%20revision_September2021.pdf
Jul 13, 2021
Europe Needs to Collect More Plasma
Plasma-derived medicinal products PDMPs), derived from human plasma from healthy donors, are essential for around 300,000 European patients who rely on these therapies to treat a variety of rare, chronic, and potentially life-threatening conditions, which are often genetic in origin.
All
Advocacy
https://assets-global.website-files.com/638f893112c6eac0e46ac576/64539bb0b145bb5b857f53a7_EU%20Position%20paper_Europe%20needs%20to%20collect%20more%20plasma.pdf
Jul 13, 2021
Europe Needs to Collect More Plasma
Plasma-derived medicinal products PDMPs), derived from human plasma from healthy donors, are essential for around 300,000 European patients who rely on these therapies to treat a variety of rare, chronic, and potentially life-threatening conditions, which are often genetic in origin.
All
Advocacy
https://assets-global.website-files.com/638f893112c6eac0e46ac576/64539bb0b145bb5b857f53a7_EU%20Position%20paper_Europe%20needs%20to%20collect%20more%20plasma.pdf
Mar 31, 2021
PPTA Supports California AB 392
The Plasma Protein Therapeutics Association (PPTA) would like to thank you for authoring Assembly Bill 392.
All
Advocacy
https://assets-global.website-files.com/638f893112c6eac0e46ac576/6453f688a121567c7026889d_PPTA%20Supports%20AB%20392%20Nazarian.pdf
Mar 31, 2021
PPTA Supports California AB 392
The Plasma Protein Therapeutics Association (PPTA) would like to thank you for authoring Assembly Bill 392.
All
Advocacy
https://assets-global.website-files.com/638f893112c6eac0e46ac576/6453f688a121567c7026889d_PPTA%20Supports%20AB%20392%20Nazarian.pdf
No results found